# Evommune Inc. (EVMN) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $12.27, market value $445 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Evommune Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 44.5×**. Each dollar of revenue is priced at 44.5×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -17.2%** (5-yr avg -73.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Net margin: -529.8%**. The company reported a net loss over the last twelve months.
- **Return on equity: -33.5%**. Return on equity is negative because earnings are negative.
- **Return on assets: -42.1%**. Each dollar of assets produces -42.1% of profit.

## Growth
- **Revenue growth (1 yr): 85.7%**. Revenue grew 85.7% over the last year.
- **EPS growth (1 yr): 75.2%**. Earnings per share rose 75.2%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 8.57** (quick 8.57). Current assets cover the next year's liabilities 8.57 times.
- **Altman Z-score: 14.66**. A Z-score of 14.66 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Evommune Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover Evommune Inc.; the consensus is buy, with an average price target of $27.63 (+125% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -63.0%** (17.2% above the low). Trading 63% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 1.18** (volatility 123%). Beta of 1.18 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EVMN · Page: https://foliofundamentals.com/stocks/evmn

Not investment advice.